Detailansicht

Wissensnetz

Person

Martina Brückmann (1970-)

Internistin

Name	Martina Brückmann
Zeit	1970- (Lebensdaten)
Ort	Deutschland
Akademischer Grad bzw. Titel	Priv.-Doz. Dr. med.
Beruf	Internistin (charakteristischer Beruf) Dozentin
Variante	Martina Maria Brückmann Martina Brueckmann Maja Brückmann (falsche Namensform)
Beziehung	Boehringer Ingelheim Pharma GmbH & Co. KG (seit 2008) Klinikum Mannheim (2000-2008) Universitätsklinikum Heidelberg (1997-2000)
Weitere Angaben	Diss. Fachbereich Humanmedizin; jetzt: Dozentin für Innere Medizin an der Medizinischen Fakultät Mannheim der Universität Heidelberg
Quelle	https://www.linkedin.com/in/martina-brueckmann-b9a326164/?originalSubdomain=de (Stand: 20.02.2023)
Datensatztyp	Person
GND-Nummer	121145069
Datensatz-ID	121145069
Beteiligt an alle anzeigen Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure Kidney function after initiation and discontinuation of empagliflozin in patients with heart failure with and without type 2 diabetes: insights from the EMPERIAL trials Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction : The EMPEROR-Preserved trial Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism Dabigatran treatment simulation in patients undergoing maintenance haemodialysis Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure : Substudy of the RE-LY trial Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure Alterations of leptin in the course of inflammation and severe sepsis Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1 Drotrecogin alfa (activated) prolongs half-life time of messenger RNA encoding for Interleukin-8 and Monocyte chemoattractant protein-1 Stabilization of monocyte chemoattractant protein-1-mRNA by activated protein C Die induzierbare NO-Synthase in glatten Gefäßmuskelzellen : Charakterisierung und funktionelle Bedeutung

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Martina Brückmann (1970-)

Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure

Kidney function after initiation and discontinuation of empagliflozin in patients with heart failure with and without type 2 diabetes: insights from the EMPERIAL trials

Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction : The EMPEROR-Preserved trial

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials

Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran

Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis

Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure : Substudy of the RE-LY trial

Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I

Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure

Alterations of leptin in the course of inflammation and severe sepsis

Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1

Drotrecogin alfa (activated) prolongs half-life time of messenger RNA encoding for Interleukin-8 and Monocyte chemoattractant protein-1

Stabilization of monocyte chemoattractant protein-1-mRNA by activated protein C

Die induzierbare NO-Synthase in glatten Gefäßmuskelzellen : Charakterisierung und funktionelle Bedeutung